A review on combinatorial therapies in Melanoma
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
| Auteur principal: | |
|---|---|
| Autres auteurs: | |
| Format: | Project report |
| Langue: | English |
| Publié: |
Brac University
2024
|
| Sujets: | |
| Accès en ligne: | http://hdl.handle.net/10361/23618 |
| id |
10361-23618 |
|---|---|
| record_format |
dspace |
| spelling |
10361-236182024-06-27T21:04:59Z A review on combinatorial therapies in Melanoma Ahmmed, Md. Kawsar Momtaz, Tanisha School of Pharmacy, Brac University Melanoma Combination therapy Ipilimumab Nivolumab Skin--Cancer. This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. Cataloged from the PDF version of the project report. Includes bibliographical references (pages 31-39). Melanoma is the most deadly form of skin cancer due to its resistance to traditional cytotoxic treatment. However, innovative treatments have changed this disease's clinical trajectory. Understanding cancer microenvironment interaction and tumor oncogenesis led to these breakthroughs. Targeting the oncogenic mitogen-activated protein kinase (MAPK) pathway, notably BRAF, and MEK, improves overall and progression-free survival for BRAF-mutant melanoma. Furthermore, recent studies have shown long-lasting responses in a number of cancers after treatment with inhibitors of the immune suppressive programmed cell death 1 receptor (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) pathways to stimulate an anti-tumour immune response. Results from treating melanoma with immune-modulating and targeted therapies are promising. There may be further improvement potential when these drugs are combined. In this review, I will discuss current immunotherapies and targeted medications, as well as the results of combination studies and possible future therapeutic approaches. Md. Kawsar Ahmmed B. Pharmacy 2024-06-27T04:33:09Z 2024-06-27T04:33:09Z 2023 2023-10 Project report ID 19346026 http://hdl.handle.net/10361/23618 en Brac University project reports are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 39 pages application/pdf Brac University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
English |
| topic |
Melanoma Combination therapy Ipilimumab Nivolumab Skin--Cancer. |
| spellingShingle |
Melanoma Combination therapy Ipilimumab Nivolumab Skin--Cancer. Ahmmed, Md. Kawsar A review on combinatorial therapies in Melanoma |
| description |
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. |
| author2 |
Momtaz, Tanisha |
| author_facet |
Momtaz, Tanisha Ahmmed, Md. Kawsar |
| format |
Project report |
| author |
Ahmmed, Md. Kawsar |
| author_sort |
Ahmmed, Md. Kawsar |
| title |
A review on combinatorial therapies in Melanoma |
| title_short |
A review on combinatorial therapies in Melanoma |
| title_full |
A review on combinatorial therapies in Melanoma |
| title_fullStr |
A review on combinatorial therapies in Melanoma |
| title_full_unstemmed |
A review on combinatorial therapies in Melanoma |
| title_sort |
review on combinatorial therapies in melanoma |
| publisher |
Brac University |
| publishDate |
2024 |
| url |
http://hdl.handle.net/10361/23618 |
| work_keys_str_mv |
AT ahmmedmdkawsar areviewoncombinatorialtherapiesinmelanoma AT ahmmedmdkawsar reviewoncombinatorialtherapiesinmelanoma |
| _version_ |
1814309453386743808 |